Dual PPAR Agonist Composition for Mitochondrial Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for increasing mitochondrial activity and improving adiponectin production are scarce or ineffective in addressing various cell-related diseases and disorders.
Innovation Solution
A pharmaceutical composition comprising a carbohydrate capable of donating multiple sulphates, such as pentosan polysulphate, combined with a PPARγ agonist like indomethacin or pioglitazone, in specific molar ratios, to enhance mitochondrial activity and adiponectin production, offering a synergistic effect that reduces toxic side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used to increase mitochondrial activity and improve adiponectin production, then therapeutic effects are achieved, but toxic side effects occur and treatment effectiveness is limited
Solution Approach 1:
The patent combines two distinct compounds with different mechanisms of action: a PPARγ agonist (which activates peroxisome proliferator-activated receptor gamma to regulate gene expression) and a PPARα/δ agonist (which activates peroxisome proliferator-activated receptor alpha/delta to enhance fatty acid oxidation). This synergistic combination achieves therapeutic effects at lower doses, reducing toxic side effects while improving treatment effectiveness for mitochondrial dysfunction and adiponectin production deficiencies.
2Reliability
If higher dosages of single compounds are used to achieve therapeutic effects, then treatment effectiveness increases, but toxic side effects increase
Solution Approach 1:
The patent changes the dosing parameters by using a combination of two compounds at lower individual dosages rather than a single compound at high dosage. The synergistic interaction between PPARγ agonist and PPARα/δ agonist allows achieving the same or better therapeutic effect with reduced total dosage, thereby minimizing toxic side effects while maintaining treatment effectiveness.
3Adaptability or versatility
If existing pharmaceutical approaches are used, then some therapeutic benefits are achieved, but the treatments are scarce and ineffective for various cell-related diseases
Solution Approach 1:
The patent develops a multi-functional pharmaceutical composition that addresses multiple aspects of mitochondrial dysfunction and metabolic disorders simultaneously. The dual-agonist approach targets both PPARγ (for adiponectin production and glucose regulation) and PPARα/δ (for fatty acid oxidation and mitochondrial function), making the treatment versatile and effective for various cell-related diseases including metabolic syndrome, cardiovascular diseases, and neurodegenerative conditions.
Data Source
AI summary
The invention relates to a pharmaceutical composition, as well as a dosage comprising said pharmaceutical composition, and a medicament for use in the treatment of a mitochondrial activity related disease or disorder and/or of an adiponectin production related disease or disorder, and said pharmaceutical composition as a medicament. It has been found that the present composition contributes positively in the recovery, the treatment, and reducing negative effects of such cell-related diseases and disorders.